ClinicalTrials.gg
RecruitingNCT07569926Updated Nov 5, 2026

Impact of Fluciclovine (18F) PET (Positron Emission Tomography) on the Management of Prostate Cancer Following Negative or Equivocal PSMA (Prostate-Specific Membrane Antigen) PET Imaging at the Time of Biochemical Recurrence

A Phase 4 interventional study of fluciclovine (18F) in Prostate Cancer, sponsored by Blue Earth Diagnostics. Recruiting at 6 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Blue Earth Diagnostics (part of Bracco) · Phase 4, Interventional, and Diagnostic

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Nov 5, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
142
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms — 2 open to participants now, 3 under way, none of them phase 3. fluciclovine F-18 · Prostatic Neoplasms.

Planned enrollment
3rd of 14
142 · median 28
Started
2026
the only one that year
Phase 4
3 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
2 of 14
Blue Earth Diagnostics

Among the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, this one is the 3rd largest by planned enrollment, is the only one that started in 2026, is one of 3 in phase 4, and was the 14th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 14 studies testing fluciclovine F-18 in Prostatic Neoplasms are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About fluciclovine F-18

fluciclovine F-18: first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing fluciclovine F-18 in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The impact of fluciclovine (18F) PET on the management of participants with prostate cancer following negative or equivocal PSMA PET Imaging at the time of biochemical recurrence

Read the detailed description

This is a prospective, multi-institutional, Phase 4 study to assess change in management (CIM) following fluciclovine (18F) imaging in participants with prostate cancer who have a negative or equivocal prostate-specific membrane antigen (PSMA) positron emission tomography (PET) scan at the time of any biochemical recurrence (BCR)

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Biochemical Recurrence (BCR)
  • Positron Emission Tomography (PET) Scan
  • Negative or equivocal PSMA PET scan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be males aged ≥18 years at Screening.
  2. Participants with suspected BCR of prostate cancer (see Inclusion Criterion #3 below) following prior curative intent treatment and a negative or equivocal PSMA PET scan with any FDA-approved PSMA PET tracer (must be within 45 days prior to Visit 2 [fluciclovine (18F) PET/CT scan]), regardless of findings on conventional imaging.
  3. Participants suspicious for a biochemically recurrent prostate cancer with a detectable or rising PSA after definitive therapy on the basis of: Post-radical prostatectomy (with or without or salvage radiation therapy): PSA that is ≥0.2 ng/mL (completed >6 weeks after surgery) or Post-radiation therapy (with or without ADT): Increase in PSA level that is ≥2.0 ng/mL above the nadir PSA level and rising PSA is confirmed on consecutive PSA determinations.
  4. Men who are sexually active with women of (WOCBP), must agree to use a highly effective method(s) of for 24 hours post-fluciclovine (18F) injection.
  5. Participants must provide written before any study-specific procedures or interventions are performed.
  6. Ability of the participants to comply with planned study procedures

Exclusion criteria

Exclusion Criteria:

  1. Participants with known castrate resistant prostate cancer.
  2. Participants with any medical condition (including intercurrent illness and uncontrolled serious infection) or circumstance (including receiving an IP) that the investigator believes may compromise the data collected or lead to a failure to comply with the study requirements.
  3. Participants who are planned to have an x-ray contrast agent or any other PET radiotracer within five physical half-lives of the first PET radionuclide prior to the study fluciclovine (18F) PET/CT scan.
  4. Participants participating in an interventional clinical trial within 30 days and having received an IP five physical half-lives prior to the study fluciclovine (18F) PET/CT scan.
  5. Participants with known to the active substance or to any of the of fluciclovine (18F).
  6. Participants who have received salvage therapy for the current episode of BCR.
  7. Participants who initiate cancer treatment (systemic or radiation therapy) or who have started any supplements or herbal medications intended to treat cancer between the PSMA PET and fluciclovine (18F) PET/CT scans.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
142 participants (estimated)

Study arms

  • Experimental
    Patients Single intravenous administration of fluciclovine (18F) for PET Scan

    Patients Single intravenous administration of fluciclovine (18F) for PET Scan

    Drug: fluciclovine (18F)

Interventions

  • fluciclovine (18F) injection, 370 MBq (10 mCi) ± 20%, delivered as an intravenous bolus.

    Also known as: Axumin

06

What researchers measure

Primary outcomes

  1. Percentage of participants with any recorded Change In Management following a fluciclovine (18F) PET/CT scan.

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

Secondary outcomes

  1. For those participants with a change in management (CIM), percentage of participants with a recorded minor or major CIM following a fluciclovine (18F) PET/CT scan.

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  2. For those participants with a CIM, summary of the CIM groups following a fluciclovine (18F) PET/CT scan.

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  3. Participant-level and region-level (prostate bed, pelvic lymph nodes [PLNs], other) detection rates.

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  4. Participant-level and region-level (prostate bed, PLNs, other) detection rates stratified by PSA levels.

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  5. Percentage of participants with any recorded CIM following a positive/negative fluciclovine (18F) PET/CT

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  6. Percentage of participants with a recorded minor or major CIM following a positive/negative fluciclovine (18F) PET/CT

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

  7. For those participants with a CIM, summary of CIM groups following a positive/negative fluciclovine (18F) PET/CT

    Time frame: fluciclovine (18F) on Day 1, At least 24 hours after the piflufolastat (18F) scan, but within 30 calendar days

07

Study locations

4 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Dec 2027, 16 months after the start.

Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's planned 16 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
May 6, 2026
StartActual
Aug 31, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2032
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites changed recruiting status (3 now recruiting)
Show 3 sites
  • Urology Austin · Austin, United StatesNot yet recruiting→Recruiting
  • Emory University · Atlanta, United StatesNot yet recruiting→Recruiting
  • Massachusetts General Hospital · Boston, United StatesNot yet recruiting→Recruiting
across 3 updates, Sep 29, 2026 – Nov 5, 2026
Show all 3 updates
  1. Nov 5, 2026
    Massachusetts General Hospital is now Recruiting
    + 1 other change: verification date
  2. Oct 7, 2026
    Emory University is now Recruiting
    + 1 other change: verification date
  3. Sep 29, 2026
    Urology Austin is now Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07569926
Responsible party
Sponsor
First posted
May 6, 2026
Start date
Aug 31, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2032 (estimated)
Last update
Nov 5, 2026

Study contacts

BED-Flc-401 Study Team
Contact
bed-flc-401_study@bracco.com
+44 (0) 1865 507300
Nadine Mallak, MD
principal investigator · Oregon Health and Science University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluciclovine F-18

Start the discussion